Plain-English translation of NCT06568562 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can help treat advanced prostate cancer that has progressed after a type of radioactive treatment called lutetium-177 PSMA therapy. is a pill you take by mouth once each day. The study will measure how well this treatment works and how safe it is over 16 weeks.
Some men's prostate cancer stops responding to the radioactive treatment and continues to grow. This medication is being tested to offer a new option for men in this situation who need additional help fighting their cancer.
You likely qualify if…
You likely don't qualify if…
You would take one pill of this medication by mouth every day for 28-day cycles. You'll visit the clinic regularly for blood tests, checkups, and scans to see how well the treatment is working and to watch for any side effects. Your doctor may adjust your dose if needed. The main focus is checking how you're doing after 16 weeks of treatment.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of Utah
Collaborators
Exelixis
Enrollment target
~32 participants
Started
December 2024
Primary completion
December 2026
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Susan Sharry
Huntsman Cancer Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.